Wellington Management Group
CARM

Wellington Management Group’s Carisma Therapeutics CARM Stock Holding History

Wellington Management Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-66,041
Closed -$279K – 1834
2023
Q3 		$279K Buy
66,041
+2,225
+3% +$14.1K ﹤0.01% 1744
2023
Q2 		$560K Buy
+63,816
New +$347K ﹤0.01% 1675

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group's CARM Position: Q4 2023 in Review

Wellington Management Group sold out of Carisma Therapeutics (CARM) in Q4 2023, closing a stake of 66,041 shares — an estimated $279K sold.

Wellington Management Group first reported a position in CARM in Q2 2023 and held it in 2 quarters. The position peaked at $560K in Q2 2023. 50 funds tracked by Wall St. Rank hold CARM as of Q4 2023.

  • Wellington Management Group reported no remaining Carisma Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Wellington Management Group sold 66,041 Carisma Therapeutics shares in Q4 2023, an estimated $279K.
  • Wellington Management Group first reported a position in Carisma Therapeutics in Q2 2023 and held it in 2 quarters.
  • Wellington Management Group's Carisma Therapeutics position peaked at $560K in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2023.

Based on Wellington Management Group's 13F filing for Q4 2023, filed 12 Feb 2024.